VYNE Therapeutics
VYNE
32 hedge funds and large institutions have $22.9M invested in VYNE Therapeutics in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
24% more capital invested
Capital invested by funds: $18.4M → $22.9M (+$4.49M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.03% less ownership
Funds ownership: 56.61% → 55.57% (-1%)
3% less funds holding
Funds holding: 33 → 32 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exome Asset Management
New York
|
+$641K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$474K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$375K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$237K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.64M |
| 2 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$481K |
| 3 |
FAM
Fred Alger Management
New York
|
-$140K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$50.6K |
| 5 |
HF
HRT Financial
New York
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $3.81K | +$972 | +451 | +57% |
|
|
MLA
27
MB, Levis & Associates
Center Valley,
Pennsylvania
| $3.2K | – | – | – |
|
28
Russell Investments Group
London,
United Kingdom
| $574 | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $535 | +$4 | +2 | +1% |
|
30
JP Morgan Chase
New York
| $520 | +$50 | +23 | +16% |
|
31
UBS Group
Zurich,
Switzerland
| $49 | -$1.79K | -830 | -98% |
|
|
CPG
32
Cornerstone Planning Group
Fairfield,
New Jersey
| $6 | +$4 | +2 | New |
|
|
SCM
33
Soleus Capital Management
Greenwich,
Connecticut
| – | -$1.64M | -703,868 | Closed |
|
|
FAM
34
Fred Alger Management
New York
| – | -$140K | -60,055 | Closed |
|
|
HF
35
HRT Financial
New York
| – | -$23K | -10,043 | Closed |
|
36
US Bancorp
Minneapolis,
Minnesota
| – | -$10.4K | -4,444 | Closed |
|
|
SPIA
37
Steward Partners Investment Advisory
New York
| – | -$51 | -22 | Closed |
|
|
ITIM
38
Indiana Trust & Investment Management
Mishawaka,
Indiana
| – | -$28 | -12 | Closed |
|
VYNE Hedge Fund Activity: Q1 2024 in Review
32 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2024, worth a combined $22.9M — up 24% from $18.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VYNE and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.
The largest buyer was Exome Asset Management, adding an estimated $641K. The largest seller was Soleus Capital Management, exiting entirely with an estimated $1.64M sold.
- 32 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2024, down from 33 in Q4 2023.
- Funds reported $22.9M of VYNE Therapeutics stock for Q1 2024, up 24% quarter-over-quarter.
- 5 funds opened new VYNE Therapeutics positions in Q1 2024 and 6 closed out, a net change of -1 holder.
- The largest VYNE Therapeutics buyer in Q1 2024 was Exome Asset Management, an estimated $641K added.
- The largest VYNE Therapeutics seller in Q1 2024 was Soleus Capital Management, an estimated $1.64M sold.
Based on aggregated 13F filings for Q1 2024.